- Home
- EDSA vs HOWL Comparison
EDSA vs HOWL Comparison
Compare EDSA & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDSA | HOWL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 48.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDSA | HOWL |
|---|---|---|
| Price | $4.05 | $0.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | $5.00 |
| AVG Volume (30 Days) | 77.0K | ★ 11.3M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.27 |
| 52 Week High | $20.32 | $2.23 |
Technical Indicators
Market Signals| Indicator | EDSA | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 68.05 |
| Support Level | $1.34 | $0.56 |
| Resistance Level | $5.10 | $1.14 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 16.69 | 78.58 |
Price Performance
Historical ComparisonAbout EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.